About Caribou Biosciences, Inc.
https://cariboubio.comCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
CEO
Rachel E. Haurwitz
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 36
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:6.95M
Value:$11.19M
PFIZER INC
Shares:4.69M
Value:$7.55M
VANGUARD GROUP INC
Shares:4.23M
Value:$6.81M
Summary
Showing Top 3 of 127
About Caribou Biosciences, Inc.
https://cariboubio.comCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.2M ▼ | $30.97M ▼ | $-27.55M ▲ | -1.25K% ▲ | $-0.3 ▲ | $-26.92M ▲ |
| Q2-2025 | $2.67M ▲ | $50.24M ▲ | $-54.1M ▼ | -2.03K% ▼ | $-0.58 ▼ | $-34.26M ▲ |
| Q1-2025 | $2.35M ▲ | $45.27M ▲ | $-39.99M ▼ | -1.7K% ▲ | $-0.43 ▼ | $-41.75M ▼ |
| Q4-2024 | $2.08M ▲ | $11.09M ▼ | $-35.49M ▼ | -1.71K% ▲ | $-0.39 ▼ | $-37.09M ▼ |
| Q3-2024 | $2.02M | $40.26M | $-34.68M | -1.71K% | $-0.38 | $-37.06M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $147.26M ▼ | $194.98M ▼ | $53.14M ▼ | $141.84M ▼ |
| Q2-2025 | $183.95M ▼ | $220.9M ▼ | $54.77M ▼ | $166.13M ▼ |
| Q1-2025 | $208.47M ▼ | $273.66M ▼ | $56.43M ▼ | $217.22M ▼ |
| Q4-2024 | $209.54M ▼ | $313.31M ▼ | $60.36M ▼ | $252.95M ▼ |
| Q3-2024 | $228.18M | $344.33M | $63.13M | $281.2M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-27.55M ▲ | $-25.18M ▲ | $10.85M ▼ | $277K ▲ | $-14.06M ▼ | $-25.3M ▲ |
| Q2-2025 | $-54.1M ▼ | $-28.26M ▲ | $24.04M ▼ | $6K ▼ | $-4.22M ▼ | $-28.68M ▲ |
| Q1-2025 | $-39.99M ▼ | $-36.73M ▼ | $49.38M ▲ | $468K ▼ | $13.12M ▲ | $-37.77M ▼ |
| Q4-2024 | $-35.49M ▼ | $-35.47M ▼ | $15.93M ▼ | $3.86M ▲ | $-15.68M ▼ | $-35.99M ▼ |
| Q3-2024 | $-34.68M | $-32.66M | $26.52M | $244K | $-5.9M | $-33.33M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Reportable Segment | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Rachel E. Haurwitz
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 36
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:6.95M
Value:$11.19M
PFIZER INC
Shares:4.69M
Value:$7.55M
VANGUARD GROUP INC
Shares:4.23M
Value:$6.81M
Summary
Showing Top 3 of 127